Brief: Xintela's GMP Facility Approved For Manufacturing Of Cell Therapy Products
21/05/2021 07:42
May 21 (Reuters) - Xintela AB XINT.ST :
* XINTELA'S GMP FACILITY APPROVED FOR MANUFACTURING OF CELL
THERAPY PRODUCTS
* RECEIVED PERMISSION FROM MEDICAL PRODUCTS AGENCY TO
PRODUCE CELL
THERAPY PRODUCTS (ATMPS), IN ITS OWN GMP FACILITY
Source text for Eikon: ID:nBQN20t35j
Further company coverage: XINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xintela AB
See all newsBrief: Xintela To Raise SEK 30 Mln Via Convertible Loan From Flerie Invest
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects